Merck & Co (MRK)
100.86
-0.97 (-0.95%)
NYSE · Last Trade: Dec 2nd, 2:51 PM EST
Detailed Quote
| Previous Close | 101.83 |
|---|---|
| Open | 101.53 |
| Bid | 100.85 |
| Ask | 100.87 |
| Day's Range | 100.31 - 101.80 |
| 52 Week Range | 73.31 - 105.84 |
| Volume | 6,540,592 |
| Market Cap | 255.31B |
| PE Ratio (TTM) | 13.32 |
| EPS (TTM) | 7.6 |
| Dividend & Yield | 3.240 (3.21%) |
| 1 Month Average Volume | 15,238,065 |
Chart
About Merck & Co (MRK)
Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
News & Press Releases
Wall Street has recently concluded a tumultuous yet ultimately resilient period, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all managing to edge higher in late November and early December 2025. This cautious comeback signals a complex market sentiment, where investors are meticulously weighing the promise
Via MarketMinute · December 2, 2025
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
BioMedWire Editorial Coverage : Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) ( Profile ), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…
Via Investor Brand Network · December 2, 2025
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) (Profile), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and Insmed Inc. (NASDAQ: INSM).
By BioMedWire · Via GlobeNewswire · December 2, 2025
There's still time to get in on these rising stars.
Via The Motley Fool · December 2, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · December 1, 2025
As December 1, 2025, dawns, global financial markets are grappling with a significant uptick in Treasury yields, a movement primarily catalyzed by a substantial sell-off in Japanese government debt and evolving expectations surrounding central bank policies. This surge has immediately cast a shadow of caution and a 'risk-off' sentiment across
Via MarketMinute · December 1, 2025
New York, NY – December 1, 2025 – U.S. Treasury yields have experienced a significant climb today, marking a pivotal moment for financial markets. This ascent, driven by a complex interplay of global monetary policy shifts, persistent inflation concerns, and the ever-growing specter of increased government borrowing, has sent immediate ripple
Via MarketMinute · December 1, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4. In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and address an unmet medical need.
By Merck Sharp & Dohme · Via Business Wire · December 1, 2025
If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio.
Via The Motley Fool · November 30, 2025
There are plenty of potential winners outside the world of AI.
Via The Motley Fool · November 30, 2025
The struggling pharmaceutical giant is showing signs of life.
Via The Motley Fool · November 29, 2025
The Dow Jones Industrial Average (DJIA) has staged a remarkable comeback, successfully erasing its November 2025 losses by the month's final trading day, Friday, November 28, 2025. This significant recovery not only marked a powerful late-month surge but also extended the index's impressive streak of monthly gains to seven, injecting
Via MarketMinute · November 28, 2025
Discover Merck (MRK), a top dividend stock with a 3.58% yield, strong growth history, and excellent profitability for reliable income.
Via Chartmill · November 28, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Citi 2025 Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 1:00 p.m. ET.
By Merck & Co., Inc. · Via Business Wire · November 26, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 8th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 2, 2025, at 9:10 a.m. ET.
By Merck Sharp & Dohme · Via Business Wire · November 26, 2025
The Dow Jones Industrial Average has been on a roller-coaster ride in November 2025, experiencing significant volatility and sending mixed signals across various sectors. While the index achieved a fresh all-time high earlier in the month, it has since grappled with an "indiscriminating sell-off" fueled by concerns over an "AI
Via MarketMinute · November 25, 2025
Check out the companies making headlines yesterday:
Via StockStory · November 25, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company's future.
Via StockStory · November 24, 2025
Biotech Valuations Rise as New Clinical Platforms Show Progress
BioMedWire Editorial Coverage : As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (“GAAP”) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( profile ) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (“JV”) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic Therapeutics’ position as a treatment leader, along with others in the oncology-treatment space, including Iovance Biotherapeutics Inc . (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and…
Via Investor Brand Network · November 24, 2025
AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (JV) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic Therapeutics’ position as a treatment leader, along with others in the oncology-treatment space, including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ).
By BioMedWire · Via GlobeNewswire · November 24, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates, with more than 20 abstracts being presented.
By Merck & Co., Inc. · Via Business Wire · November 24, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry.
Via StockStory · November 23, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Via StockStory · November 21, 2025
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited “mini-tender” offer, dated November 10, 2025, to purchase up to 1,000,000 shares of Merck common stock at $65.00 per share. The offer price is approximately 24.66% below the closing price of Merck common stock on November 7, 2025 ($86.28), the last trading day before the date of the offer, and approximately 31.56% below the closing price of Merck common stock on November 20, 2025 ($94.97), the day prior to this release.
By Merck & Co., Inc. · Via Business Wire · November 21, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. These approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population.
By Merck & Co., Inc. · Via Business Wire · November 21, 2025